Earlier this month (July 10, 2026), the German authorities voted by a sweeping set of provisions set to considerably affect medical hashish sufferers who’ve their prescriptions coated by their statutory medical health insurance.
Yesterday (July 29), this was revealed unchanged into the Federal Gazette, seeing the ban on prescribing hashish flower by statutory medical health insurance take impact on 30 July with no transitional safety, even for sufferers whose remedy is already authorized and beneath method.
Regardless of the Bundesverband Hashish Wirtschaft (BvCW) calling for the federal government to refer the invoice to a mediation committee (Vermittlungsausschuss), this was instantly declined by the Bundesrat on the identical day the legislation handed, in line with the chamber’s personal report (BR-Drs. 411/26).
With the parliamentary route exhausted, the battle has moved to the courts, and a scramble over how the legislation is to be utilized.
Atone for the story thus far…
Germany Bans Hashish Flowers from GKV and Mandates Six-Month Trial for Extracts
Germany has as we speak voted to ban medical hashish flower from its statutory medical health insurance scheme, in a controversial transfer critics say may have an outsized affect on the ‘severely sick’. […]
Learn Now →
‘Double burden’ on severely sick
Provision §31(6) SGB V (BGBl. 2026 I Nr. 228) was reworked by the legislative course of between April and 10 July, and now does two issues.
It removes dried flower from the particular reimbursement entitlement outright, a measure which was baked into the invoice early.
Later, one other measure was bolted onto this already controversial value saving invoice requiring any new prescription of extracts, dronabinol or nabilone be preceded by a compulsory six-month trial of an authorized cannabis-based completed medication.
Based on the Bundesverband pharmazeutischer Cannabinoidunternehmen (BPC), a pharmaceutical cannabinoid business physique, that is set to affect some 65,000 sufferers in established hashish remedy reimbursed by statutory insurance coverage.
The BPC stated the legislation imposed a ‘double burden’ on the severely sick, stripping a very susceptible group of a confirmed remedy whereas forcing everybody else by a six-month detour. It’s calling for the blanket flower exclusion to be withdrawn and for the finished-medicine precedence to use ‘solely the place an authorized and deliverable preparation is definitely accessible’.
Equally, the Bund Deutscher Hashish-Patienten (BDCan) wrote to Federal President Frank-Walter Steinmeier asking him to look at the brand new guidelines for constitutional defects earlier than signing them into pressure beneath Article 82(1) of the Fundamental Regulation.
The affiliation argued that the wording left it unclear whether or not the six-month trial utilized to current, already-authorised therapies, and warned that no authorized inhalable completed medication exists in Germany to switch flower for sufferers who want rapid-onset reduction, together with palliative instances.
‘Severely sick folks should not lose their confirmed remedy in a single day,’ stated Daniela Joachim, Chair of the BDCan. ‘That is about safety of provide, and about not interrupting ongoing remedies unnecessarily.’
‘Every little thing in our energy to overturn this legislation’
On 19 July, the Arbeitsgemeinschaft Hashish als Medizin (ACM) introduced that its board had resolved to file a constitutional grievance (Verfassungsbeschwerde) towards the legislation on the Federal Constitutional Courtroom.
The grievance might be introduced by Professor Oliver Tolmein, a lawyer with a monitor report in hashish take a look at instances earlier than Germany’s social and administrative courts.
The ACM’s chairman, Dr Franjo Grotenhermen, wrote that the laws ‘wrongly assumes that hashish medicines are interchangeable’, including that this ‘isn’t the case’.
The affiliation stated the Deutscher Hanfverband (DHV) had pledged its help and that it could open a devoted donation account to fund the case.
The extra instant downside is that the legislation takes impact earlier than the way it will work in follow has been clarified.
As a result of the 4 authorized completed medicines carry slender licences, Sativex for multiple-sclerosis spasticity, Epidyolex for sure epilepsies, Canemes for chemotherapy-related nausea and Exilby for power again ache, most sufferers handled beneath §31(6) don’t have any on-label possibility. Any mandated trial would subsequently run off-label, a route statutory insurers reimburse solely in distinctive instances.
“For almost all of ailments for which hashish is presently used beneath §31(6) SGB V, there is no such thing as a authorized ready-to-use hashish medication,” the medical hashish distributor Materia Deutschland wrote on LinkedIn, warning that off-label use ‘must rapidly advance from the exception to the rule’ if the legislation stands.
Pharmacies and distributors are actually urgent insurers and the Medizinischer Dienst for concrete steering on points like when the six-month trial may be waived or shortened, how palliative care, paediatric sufferers, tube feeding, swallowing issues, intolerances and contraindications are to be dealt with, and what documentation the medical service would require.
READ MORE…
No profit for insurers
The amendments have been handed as a part of a broader value management invoice, meant to considerably scale back the monetary burden of Germany’s statutory medical health insurance scheme.
Dr Alessandro Rossoni, co-founder and managing director of the medical hashish wholesaler Nimbus Well being, argued on LinkedIn that the state might have captured many of the financial savings with out eradicating anybody from remedy, just by repricing the flower somewhat than delisting it.
Hilfstaxe, the tariff that governs what pharmacies invoice insurers, fixes reimbursement for hashish flower at €9.52 per gram plus a tiered surcharge, a price the open market has lengthy undercut. Based on Rossoni, a 40-gram month-to-month prescription prices a statutory insurer about €720, towards roughly €210 for a similar flower purchased privately in the identical pharmacy on the late-2025 self-payer common of €5.23 per gram.
GAmSi knowledge, the statutory insurers’ official quarterly reporting on what the funds prescribe and spend, put mixed flower-and-extract spending at roughly €205m in 2025 (per the BvCW), of which about €124.7m went on flower (per Rossoni’s evaluation).
Repricing to the market price would have minimize that to round €36m, a saving of about 71%, ‘with out taking remedy away from a single affected person’.
Rossoni estimates that round 14,500 folks rely constantly on reimbursed flower. He goes on to level out that the identical tariff already ties dronabinol reimbursement to the precise pharmacy buy worth, which means a viable market-linked mannequin is already getting used.
“As a substitute of a scalpel, they used a machete,” he said.
The federal government defends the broader bundle as essential to stabilise contribution charges towards a structural funding hole it initiatives might attain €40bn by 2030.
Even insurers are usually not satisfied the measure will save what the federal government hopes. In its response to the April draft, the GKV-Spitzenverband, the umbrella physique for the statutory funds, expressly backed eradicating flower from reimbursement, citing the persistent lack of proof and issues over medication security and a desire for standardised, licensed cannabinoid merchandise.
Nevertheless it conceded that the roughly €130m financial savings goal ‘won’t be achievable given the anticipated excessive switch-rate to different provide by extracts or completed medicines’.
In essence, they’re saying that the federal government’s €130m ‘saving’ assumes that when you cease reimbursing flower, the insurers merely cease spending that €130m. The GKV-SV factors out that these sufferers don’t vanish, and most will swap to alternate options like extracts, or the completed medicines the brand new rule pushes them towards. As such the spending merely strikes, it doesn’t disappear.
How the rule was added
Past the change itself, how the six-month extract gateway was added has confirmed one of the controversial elements of this story.
As famous above, it didn’t seem within the authorities’s authentic invoice, which solely eliminated flower, however entered by a coalition modification within the Bundestag well being committee on 8 July, two days earlier than the vote.
The mechanism had been floated weeks earlier at a committee listening to on 22 June, the place the then-chairman of the Federal Joint Committee (G-BA), Professor Josef Hecken, advised MPs {that a} obligatory six-month trial of an authorized completed medication earlier than pharmacy preparations was conceivable, and that hashish full-extracts could possibly be named explicitly within the legislation.
Hecken retired on 30 June and was succeeded by Sonja Optendrenk.
What’s subsequent?
With the President’s signature settled, the ACM’s grievance at Karlsruhe turns into the principle path to unwinding the legislation, however constitutional instances transfer slowly.
Within the close to time period, the decisive query is whether or not the GKV-Spitzenverband and the Medizinischer Dienst publish binding exemption and implementation standards earlier than sufferers are compelled off their reimbursed remedies.
In the meantime, the business gateway for the most important affected person cohort, chronic-pain sufferers, stays open in legislation however closed in follow.
The closest on-label possibility for them is Exilby, a full-spectrum extract for power again ache from the Munich firm Vertanical, which was authorized in June however has but to succeed in the reimbursed market.
Vertanical units Exilby’s worth for its first six months on sale earlier than a reimbursed price is negotiated with the statutory insurers, and sufferers are being funnelled onto it throughout exactly that window.
Earlier this month (July 10, 2026), the German authorities voted by a sweeping set of provisions set to considerably affect medical hashish sufferers who’ve their prescriptions coated by their statutory medical health insurance.
Yesterday (July 29), this was revealed unchanged into the Federal Gazette, seeing the ban on prescribing hashish flower by statutory medical health insurance take impact on 30 July with no transitional safety, even for sufferers whose remedy is already authorized and beneath method.
Regardless of the Bundesverband Hashish Wirtschaft (BvCW) calling for the federal government to refer the invoice to a mediation committee (Vermittlungsausschuss), this was instantly declined by the Bundesrat on the identical day the legislation handed, in line with the chamber’s personal report (BR-Drs. 411/26).
With the parliamentary route exhausted, the battle has moved to the courts, and a scramble over how the legislation is to be utilized.
Atone for the story thus far…
Germany Bans Hashish Flowers from GKV and Mandates Six-Month Trial for Extracts
Germany has as we speak voted to ban medical hashish flower from its statutory medical health insurance scheme, in a controversial transfer critics say may have an outsized affect on the ‘severely sick’. […]
Learn Now →
‘Double burden’ on severely sick
Provision §31(6) SGB V (BGBl. 2026 I Nr. 228) was reworked by the legislative course of between April and 10 July, and now does two issues.
It removes dried flower from the particular reimbursement entitlement outright, a measure which was baked into the invoice early.
Later, one other measure was bolted onto this already controversial value saving invoice requiring any new prescription of extracts, dronabinol or nabilone be preceded by a compulsory six-month trial of an authorized cannabis-based completed medication.
Based on the Bundesverband pharmazeutischer Cannabinoidunternehmen (BPC), a pharmaceutical cannabinoid business physique, that is set to affect some 65,000 sufferers in established hashish remedy reimbursed by statutory insurance coverage.
The BPC stated the legislation imposed a ‘double burden’ on the severely sick, stripping a very susceptible group of a confirmed remedy whereas forcing everybody else by a six-month detour. It’s calling for the blanket flower exclusion to be withdrawn and for the finished-medicine precedence to use ‘solely the place an authorized and deliverable preparation is definitely accessible’.
Equally, the Bund Deutscher Hashish-Patienten (BDCan) wrote to Federal President Frank-Walter Steinmeier asking him to look at the brand new guidelines for constitutional defects earlier than signing them into pressure beneath Article 82(1) of the Fundamental Regulation.
The affiliation argued that the wording left it unclear whether or not the six-month trial utilized to current, already-authorised therapies, and warned that no authorized inhalable completed medication exists in Germany to switch flower for sufferers who want rapid-onset reduction, together with palliative instances.
‘Severely sick folks should not lose their confirmed remedy in a single day,’ stated Daniela Joachim, Chair of the BDCan. ‘That is about safety of provide, and about not interrupting ongoing remedies unnecessarily.’
‘Every little thing in our energy to overturn this legislation’
On 19 July, the Arbeitsgemeinschaft Hashish als Medizin (ACM) introduced that its board had resolved to file a constitutional grievance (Verfassungsbeschwerde) towards the legislation on the Federal Constitutional Courtroom.
The grievance might be introduced by Professor Oliver Tolmein, a lawyer with a monitor report in hashish take a look at instances earlier than Germany’s social and administrative courts.
The ACM’s chairman, Dr Franjo Grotenhermen, wrote that the laws ‘wrongly assumes that hashish medicines are interchangeable’, including that this ‘isn’t the case’.
The affiliation stated the Deutscher Hanfverband (DHV) had pledged its help and that it could open a devoted donation account to fund the case.
The extra instant downside is that the legislation takes impact earlier than the way it will work in follow has been clarified.
As a result of the 4 authorized completed medicines carry slender licences, Sativex for multiple-sclerosis spasticity, Epidyolex for sure epilepsies, Canemes for chemotherapy-related nausea and Exilby for power again ache, most sufferers handled beneath §31(6) don’t have any on-label possibility. Any mandated trial would subsequently run off-label, a route statutory insurers reimburse solely in distinctive instances.
“For almost all of ailments for which hashish is presently used beneath §31(6) SGB V, there is no such thing as a authorized ready-to-use hashish medication,” the medical hashish distributor Materia Deutschland wrote on LinkedIn, warning that off-label use ‘must rapidly advance from the exception to the rule’ if the legislation stands.
Pharmacies and distributors are actually urgent insurers and the Medizinischer Dienst for concrete steering on points like when the six-month trial may be waived or shortened, how palliative care, paediatric sufferers, tube feeding, swallowing issues, intolerances and contraindications are to be dealt with, and what documentation the medical service would require.
READ MORE…
No profit for insurers
The amendments have been handed as a part of a broader value management invoice, meant to considerably scale back the monetary burden of Germany’s statutory medical health insurance scheme.
Dr Alessandro Rossoni, co-founder and managing director of the medical hashish wholesaler Nimbus Well being, argued on LinkedIn that the state might have captured many of the financial savings with out eradicating anybody from remedy, just by repricing the flower somewhat than delisting it.
Hilfstaxe, the tariff that governs what pharmacies invoice insurers, fixes reimbursement for hashish flower at €9.52 per gram plus a tiered surcharge, a price the open market has lengthy undercut. Based on Rossoni, a 40-gram month-to-month prescription prices a statutory insurer about €720, towards roughly €210 for a similar flower purchased privately in the identical pharmacy on the late-2025 self-payer common of €5.23 per gram.
GAmSi knowledge, the statutory insurers’ official quarterly reporting on what the funds prescribe and spend, put mixed flower-and-extract spending at roughly €205m in 2025 (per the BvCW), of which about €124.7m went on flower (per Rossoni’s evaluation).
Repricing to the market price would have minimize that to round €36m, a saving of about 71%, ‘with out taking remedy away from a single affected person’.
Rossoni estimates that round 14,500 folks rely constantly on reimbursed flower. He goes on to level out that the identical tariff already ties dronabinol reimbursement to the precise pharmacy buy worth, which means a viable market-linked mannequin is already getting used.
“As a substitute of a scalpel, they used a machete,” he said.
The federal government defends the broader bundle as essential to stabilise contribution charges towards a structural funding hole it initiatives might attain €40bn by 2030.
Even insurers are usually not satisfied the measure will save what the federal government hopes. In its response to the April draft, the GKV-Spitzenverband, the umbrella physique for the statutory funds, expressly backed eradicating flower from reimbursement, citing the persistent lack of proof and issues over medication security and a desire for standardised, licensed cannabinoid merchandise.
Nevertheless it conceded that the roughly €130m financial savings goal ‘won’t be achievable given the anticipated excessive switch-rate to different provide by extracts or completed medicines’.
In essence, they’re saying that the federal government’s €130m ‘saving’ assumes that when you cease reimbursing flower, the insurers merely cease spending that €130m. The GKV-SV factors out that these sufferers don’t vanish, and most will swap to alternate options like extracts, or the completed medicines the brand new rule pushes them towards. As such the spending merely strikes, it doesn’t disappear.
How the rule was added
Past the change itself, how the six-month extract gateway was added has confirmed one of the controversial elements of this story.
As famous above, it didn’t seem within the authorities’s authentic invoice, which solely eliminated flower, however entered by a coalition modification within the Bundestag well being committee on 8 July, two days earlier than the vote.
The mechanism had been floated weeks earlier at a committee listening to on 22 June, the place the then-chairman of the Federal Joint Committee (G-BA), Professor Josef Hecken, advised MPs {that a} obligatory six-month trial of an authorized completed medication earlier than pharmacy preparations was conceivable, and that hashish full-extracts could possibly be named explicitly within the legislation.
Hecken retired on 30 June and was succeeded by Sonja Optendrenk.
What’s subsequent?
With the President’s signature settled, the ACM’s grievance at Karlsruhe turns into the principle path to unwinding the legislation, however constitutional instances transfer slowly.
Within the close to time period, the decisive query is whether or not the GKV-Spitzenverband and the Medizinischer Dienst publish binding exemption and implementation standards earlier than sufferers are compelled off their reimbursed remedies.
In the meantime, the business gateway for the most important affected person cohort, chronic-pain sufferers, stays open in legislation however closed in follow.
The closest on-label possibility for them is Exilby, a full-spectrum extract for power again ache from the Munich firm Vertanical, which was authorized in June however has but to succeed in the reimbursed market.
Vertanical units Exilby’s worth for its first six months on sale earlier than a reimbursed price is negotiated with the statutory insurers, and sufferers are being funnelled onto it throughout exactly that window.
Hashish Regulation Assets in Poland
Discover important authorized pages about hashish cultivation, gross sales, and medical product laws in Poland. These assets will information you thru permissions, certifications, and compliance necessities.
-
Polish News Registration and Interests of Cannabis Businesses
-
Permissions for Cannabis Sales in Poland
-
Authorization for Importing or Manufacturing Medical Products
-
Permission for Manufacturing or Importing Medical Products
-
Certificate of Good Manufacturing Practices (GMP)
-
Registration of Medical Products in Poland